Remove topic mergers-and-acquisitions
article thumbnail

Oculis enters merger deal with European Biotech Acquisition

Pharmaceutical Technology

Oculis has signed a definitive business combination agreement with special purpose acquisition company (SPAC) European Biotech Acquisition (EBAC). OCS-02 is a topical anti-TNF alpha monoclonal antibody fragment, while OCS-05 is an activator of serum-glucocorticoid kinase 2.

article thumbnail

NKGen Biotech signs agreement to merge with Graf Acquisition

Pharmaceutical Technology

NKGen Biotech, a clinical-stage natural killer (NK) cell therapy firm, has signed a definitive agreement to combine its business operations with Graf Acquisition. The merger is scheduled to be completed by the third quarter of 2023. Topic sponsors are not involved in the creation of editorial content.

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Siegfried buys 95% stake in biotechnology firm DiNAMIQS

Pharmaceutical Technology

The deal includes an option for Siegfried to purchase this remaining 5% five years after the acquisition. Topic sponsors are not involved in the creation of editorial content. Siegfried will leverage DiNAMIQS’ capabilities to commercial scale by constructing a facility that complies with good manufacturing practice standards.

52
article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. AstraZeneca & Alexion.

article thumbnail

Liminatus Pharma enters SPAC merger deal with Iris Acquisition

Pharmaceutical Technology

Liminatus Pharma has entered a definitive business combination agreement with special purpose acquisition company (SPAC) Iris Acquisition to create a business with a pro forma enterprise value of nearly $334m. The boards of directors of both companies have granted approval for the merger. Free Whitepaper.

article thumbnail

Looking back at 2022: The top healthcare stories

Pharmaceutical Technology

Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced. Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced.

Vaccines 122
article thumbnail

Informa Connect’s Compliance Congress for Specialty Products

Drug Channels

Exclusive Offer – View the full agenda and register today. Use promo code SPECIALTY10 to save 10% off* your registration fee. Informa Connect will see you there! Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply. Drug Channels, or any of its employees.